newsfilter
← Latest News
PR Newswire·

American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education

JAZZ
  • The American Nutrition Association (ANA) & Jazz Pharmaceuticals launched a joint initiative to provide evidence-based nutritional education for patients with narcolepsy or idiopathic hypersomnia (IH).
  • The collaboration aims to address elevated cardiovascular (CV) & cardiometabolic (CM) risks in these populations by promoting lower sodium intake.
  • Patients with narcolepsy or IH experience higher prevalence of CV comorbidities at younger ages, where sodium from food & medications plays a clinically meaningful role in increasing blood pressure.
  • Excess dietary sodium is a modifiable risk factor for hypertension & cardiovascular disease (CVD), which accounts for approximately 700,000 deaths annually in the US.
  • The average American consumes upwards of 3,400 mg of sodium daily, nearly 50% above the recommended upper limit of 1,500 to 2,300 mg.
  • ANA CEO Corinne Bush emphasized that nutrition is a science & excess sodium is a major modifiable contributor to elevated blood pressure & CV risk.
  • The partnership will provide patients with credible resources to understand total sodium exposure & empower healthcare providers with evidence-based tools for patient conversations.
  • Jazz Pharmaceuticals SVP Sarah McMahon stated the collaboration merges scientific rigor with patient-centered education to transform outcomes beyond medicines alone.
  • Further details on programming & resources will be released as the collaboration progresses.